Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Blood Transfusion

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Celebrating ANNA's 45th Anniversary: Specialty Practice Networks.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association·2014

Same author

Management of surgical patients with bleeding disorders.

Journal of infusion nursing : the official publication of the Infusion Nurses Society·2014

Same author

Building a new therapeutic apheresis service.

Journal of clinical apheresis·2010

Same author

Hemodialysis special interest group networking session: A European perspective on vascular access management.

Nephrology nursing journal : journal of the American Nephrology Nurses' Association·2006

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Recombinant infusion therapies indicated for bleeding disorders.

Judy Kauffman¹

¹Children's Mercy Hospital and Clinics, Kansas City, Missouri 64108, USA. jakauffman@cmh.edu

Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society

|January 18, 2011

Summary

Hemophilia treatments have evolved from risky early products to safer recombinant factors, improving patient longevity and quality of life. Ongoing research promises even more advanced therapies for bleeding disorders.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 5, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

Hematology
Genetic Disorders
Pharmacology

Background:

Hemophilia A, B, and von Willebrand's disease are inherited bleeding disorders.
Historical treatments posed risks, including serious viral infections.
Recombinant-factor products revolutionized hemophilia care.

Purpose of the Study:

To review the epidemiology and pathophysiology of hemophilia A, B, and von Willebrand's disease.
To outline the development of hemophilia treatment products.
To discuss the advantages and disadvantages of various treatment modalities and emerging therapies.

Main Methods:

Literature review of epidemiological and pathophysiological data.
Analysis of the historical development of hemophilia treatment products.
Evaluation of current and investigational treatment options.

Main Results:

Recombinant-factor therapies have significantly improved life expectancy and quality of life for patients.
Various treatment products have distinct advantages and disadvantages.
Newer products are under rapid development, showing promising advancements.

Conclusions:

The evolution of hemophilia treatment has led to substantial patient benefit.
Understanding the pathophysiology and epidemiology is crucial for effective management.
Continued research and development are vital for future therapeutic innovations in bleeding disorders.